These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38038444)

  • 1. Biomimetic Design of Peptide Inhibitor to Block CD47/SIRPα Interactions.
    Zheng S; Ji Y; Li N; Zhang L
    Langmuir; 2023 Dec; 39(49):18101-18112. PubMed ID: 38038444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
    Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
    PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations.
    Huang K; Liu Y; Wen S; Zhao Y; Ding H; Liu H; Kong DX
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
    Hatherley D; Lea SM; Johnson S; Barclay AN
    J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
    Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
    PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
    Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
    Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47.
    Liu Y; Tong Q; Zhou Y; Lee HW; Yang JJ; Bühring HJ; Chen YT; Ha B; Chen CX; Yang Y; Zen K
    J Mol Biol; 2007 Jan; 365(3):680-93. PubMed ID: 17070842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair.
    Gao J; Pang Z; Wang Q; Tan Y; Li Q; Tan H; Chen J; Yakufu W; Wang Z; Yang H; Zhang J; Sun D; Weng X; Wang Q; Qian J; Song Y; Huang Z; Ge J
    Adv Sci (Weinh); 2024 Jun; 11(24):e2306388. PubMed ID: 38477522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.